Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mu Sun

Showing results (201-210 of 338) with videos related to

Pageof 34
Sort By:
Esophagus : Official Journal of the Japan Esophageal Society|December 11, 2023
Prognostic role of pathologic status other than complete response after neoadjuvant therapy followed by surgery in esophageal squamous cell carcinomaSeong Yong Park, Junghee Lee, Dongryul Oh, et al.
Cancer Research and Treatment|October 17, 2023
Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II StudySehhoon Park, Yurimi Lee, Jiyun Lee, et al.
The Lancet. Oncology|December 25, 2025
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trialChih-Hung Hsu, Zhihao Lu, Shegan Gao, et al.
Expert Opinion on Investigational Drugs|August 1, 2020
Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumorsSeokuee Kim, Sujong Kim, Young Suk Park, et al.
Scientific Reports|November 5, 2020
Regulatory (FoxP3<sup>+</sup>) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancerJiae Koh, Joon Young Hur, Kyoung Young Lee, et al.
Cancer Research and Treatment|March 19, 2026
Phase II Efficacy and Safety of Pembrolizumab with Platinum Based Chemotherapy in Non-Small Cell Lung Cancer Patients with Untreated, Asymptomatic Brain Metastasis (PHOEBS)Junkyu Kim, Miran Han, Jinyong Kim, et al.
Cancer Research and Treatment|July 28, 2018
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in KoreaSeonggyu Byeon, Youjin Kim, Sung Won Lim, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|August 10, 2024
Comparison of the treatment outcomes of different neoadjuvant chemoradiotherapy regimens for resectable locally advanced esophageal cancerHyunki Park, Kyungmi Yang, Jae Myoung Noh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 23, 2015
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase InhibitorsJi Yun Lee, Bo Mi Ku, Sung Hee Lim, et al.
Oncotarget|November 9, 2016
A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)Hye Ryun Kim, Joung Soon Jang, Jong-Mu Sun, et al.
Pageof 34

Showing results (201-210 of 338) with videos related to

Sort By:
Pageof 34
Esophagus : Official Journal of the Japan Esophageal Society|December 11, 2023
Prognostic role of pathologic status other than complete response after neoadjuvant therapy followed by surgery in esophageal squamous cell carcinomaSeong Yong Park, Junghee Lee, Dongryul Oh, et al.
Cancer Research and Treatment|October 17, 2023
Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II StudySehhoon Park, Yurimi Lee, Jiyun Lee, et al.
The Lancet. Oncology|December 25, 2025
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trialChih-Hung Hsu, Zhihao Lu, Shegan Gao, et al.
Expert Opinion on Investigational Drugs|August 1, 2020
Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumorsSeokuee Kim, Sujong Kim, Young Suk Park, et al.
Scientific Reports|November 5, 2020
Regulatory (FoxP3<sup>+</sup>) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancerJiae Koh, Joon Young Hur, Kyoung Young Lee, et al.
Cancer Research and Treatment|March 19, 2026
Phase II Efficacy and Safety of Pembrolizumab with Platinum Based Chemotherapy in Non-Small Cell Lung Cancer Patients with Untreated, Asymptomatic Brain Metastasis (PHOEBS)Junkyu Kim, Miran Han, Jinyong Kim, et al.
Cancer Research and Treatment|July 28, 2018
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in KoreaSeonggyu Byeon, Youjin Kim, Sung Won Lim, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|August 10, 2024
Comparison of the treatment outcomes of different neoadjuvant chemoradiotherapy regimens for resectable locally advanced esophageal cancerHyunki Park, Kyungmi Yang, Jae Myoung Noh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 23, 2015
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase InhibitorsJi Yun Lee, Bo Mi Ku, Sung Hee Lim, et al.
Oncotarget|November 9, 2016
A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)Hye Ryun Kim, Joung Soon Jang, Jong-Mu Sun, et al.
Pageof 34